OBJECTIVES:  To perform cost-effectiveness analysis of brentuximab vedotin (BV) in patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma (HL). METHODS:  Markov model developed by BV manufacturer was used to assess cost-effectiveness of BV vs chemotherapy with or without radiotherapy (Ch ± RT) and vs Ch ± RT + allogeneic stem cell transplantation (alloSCT); the latest for patients eligible for alloSCT only. Direct medical costs were calculated from Russian health care system perspective. Incremental cost-effectiveness ratio (ICER) per life year (LY) was calculated for BV vs Ch ± RT and for Ch ± RT + alloSCT vs Ch ± RT. ICER for BV vs other alternatives was compared with ICER for some other drugs already included into the Russian Vital and Essential Drugs List (VEDL). RESULTS:  In patients with relapsed or refractory CD30-positive HL after autologous stem cell transplantation (ASCT) ICER was 86.4 thousands euro per LY for BV vs Ch ± RT and 95.2 thousands euro for Ch ± RT + alloSCT vs Ch ± RT. Nevertheless, the drugs with higher ICER per LY are already included into VEDL: for example bevacizumab and eribulin. The results of the study were converted from rubles to euro using the average weighted exchange rate for 2015 – 66.78 rubles for 1 euro. CONCLUSIONS:  In patients with relapsed or refractory CD30-positive HL after ASCT BV is an appropriate alternative as ICER per LY is lower than for standard treatment Ch ± RT + alloSCT vs Ch ± RT. Also ICER is lower than for other oncologic drugs included into Russian VEDL.